使用固定复方制剂治疗多种血脂异常——聚焦于缓释烟酸与辛伐他汀
Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatin.
作者信息
Pandian Anbu, Arora Anjali, Sperling Laurence S, Khan Bobby V
机构信息
Emory University School of Medicine and Grady Memorial Hospital Vascular Research, Atlanta, Georgia 30303, USA.
出版信息
Vasc Health Risk Manag. 2008;4(5):1001-9. doi: 10.2147/vhrm.s3460.
Abstract
Dyslipidemia is a major risk factor in the initiation and progression of cardiovascular diseases such as atherosclerosis. Several pharmacological agents have been developed over the past 50 years which target various lipid components such as low density lipoprotein (LDL) cholesterol, triglyceride, and high density lipoprotein (HDL) cholesterol. Similar to other risk factors such as hypertension and diabetes mellitus, the management of dyslipidemia can be complicated and may require combination therapy for effective treatment. This review discusses the biochemical mechanisms of action and clinical uses for simvastatin (the most widely available and commercially prescribed statin) and niacin, and the combination of these agents in the management and treatment of dyslipidemia.
摘要
血脂异常是动脉粥样硬化等心血管疾病发生和发展的主要危险因素。在过去50年里，已经研发出了几种针对各种脂质成分的药物，如低密度脂蛋白（LDL）胆固醇、甘油三酯和高密度脂蛋白（HDL）胆固醇。与高血压和糖尿病等其他危险因素类似，血脂异常的管理可能很复杂，可能需要联合治疗才能有效治疗。本综述讨论了辛伐他汀（最广泛使用且商业上处方最多的他汀类药物）和烟酸的生化作用机制及临床用途，以及这些药物联合用于血脂异常的管理和治疗。
相似文献
1
Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatin.
Vasc Health Risk Manag. 2008;4(5):1001-9. doi: 10.2147/vhrm.s3460.
2
Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin.
Vasc Health Risk Manag. 2009;5(1):31-43. doi: 10.2147/vhrm.s3190. Epub 2009 Apr 8.
3
Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Am J Cardiovasc Drugs. 2008;8(2):69-81. doi: 10.2165/00129784-200808020-00001.
4
Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia.
Vasc Health Risk Manag. 2014 May 7;10:279-90. doi: 10.2147/VHRM.S58694. eCollection 2014.
5
Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy.
Vasc Health Risk Manag. 2012;8:39-44. doi: 10.2147/VHRM.S22601. Epub 2012 Jan 25.
6
Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.
J Clin Hypertens (Greenwich). 2006 Jul;8(7):493-9; quiz 500-1. doi: 10.1111/j.1524-6175.2006.05505.x.
7
Niacin extended release (ER)/simvastatin (Simcor®): a guide to its use in lipid regulation.
Drugs R D. 2010;10(4):253-60. doi: 10.2165/11202560-000000000-00000.
8
Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients.
J Am Heart Assoc. 2013 Aug 7;2(4):e000037. doi: 10.1161/JAHA.113.000037.
9
Effects of Extended-Release Niacin on Quartile Lp-PLA Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline Levels of HDL-Cholesterol: Post Hoc Analysis of the AIM HIGH Trial.
J Cardiovasc Pharmacol Ther. 2019 Nov;24(6):534-541. doi: 10.1177/1074248419852955. Epub 2019 May 26.
10
A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.
Expert Opin Investig Drugs. 2010 Mar;19(3):437-49. doi: 10.1517/13543781003623223.
引用本文的文献
1
Using adipose-derived mesenchymal stem cells to fight the metabolic complications of obesity: Where do we stand?
Obes Rev. 2022 May;23(5):e13413. doi: 10.1111/obr.13413. Epub 2022 Jan 5.
2
Factors Associated with Medication Non-Adherence in Patients with Dyslipidemia.
Healthcare (Basel). 2021 Jun 28;9(7):813. doi: 10.3390/healthcare9070813.
3
Novel HI120 Affects Lipid Metabolism in C57BL/6 Obese Mice.
Front Vet Sci. 2020 Oct 14;7:560241. doi: 10.3389/fvets.2020.560241. eCollection 2020.
4
Latent Profiles Based on Light Physical Activity, Sedentary Behavior, Perceived Body Shape, and Body Mass Index in Patients with Dyslipidemia Influence Their Quality of Life.
Int J Environ Res Public Health. 2019 Oct 21;16(20):4034. doi: 10.3390/ijerph16204034.
5
The Impact of Dyslipidemia on the Health-Related Quality of Life of Korean Females Aged 50 Years and Older.
Iran J Public Health. 2019 Mar;48(3):556-558.
6
Association of periodontitis with rheumatoid arthritis and atherosclerosis: Novel paradigms in etiopathogeneses and management?
Open Access Rheumatol. 2010 May 28;2:1-16. doi: 10.2147/oarrr.s10928. eCollection 2010.
7
Combination treatment of experimental stroke with Niaspan and Simvastatin, reduces axonal damage and improves functional outcome.
J Neurol Sci. 2010 Jul 15;294(1-2):107-11. doi: 10.1016/j.jns.2010.03.020. Epub 2010 May 7.
本文引用的文献
1
The safety of niacin in the US Food and Drug Administration adverse event reporting database.
Am J Cardiol. 2008 Apr 17;101(8A):9B-13B. doi: 10.1016/j.amjcard.2008.02.027.
2
Safety of niacin and simvastatin combination therapy.
Am J Cardiol. 2008 Apr 17;101(8A):3B-8B. doi: 10.1016/j.amjcard.2008.02.026.
3
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
Am J Cardiol. 2008 Mar 1;101(5):625-30. doi: 10.1016/j.amjcard.2007.10.023. Epub 2007 Dec 21.
4
The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
Int J Clin Pract. 2007 Nov;61(11):1942-8. doi: 10.1111/j.1742-1241.2007.01597.x.
5
Nicotinic acid receptor subtypes and their ligands.
Med Res Rev. 2007 May;27(3):417-33. doi: 10.1002/med.20102.
6
Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment.
Int J Clin Pract. 2006 Jun;60(6):707-15. doi: 10.1111/j.1368-5031.2006.00957.x.
7
Impaired beta-cell function in human aging: response to nicotinic acid-induced insulin resistance.
J Clin Endocrinol Metab. 2006 Sep;91(9):3303-9. doi: 10.1210/jc.2006-0913. Epub 2006 Jun 6.
8
Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.
Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6682-7. doi: 10.1073/pnas.0601574103. Epub 2006 Apr 14.
9
Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis.
J Am Coll Cardiol. 2005 Nov 15;46(10):1855-62. doi: 10.1016/j.jacc.2005.05.085. Epub 2005 Oct 24.
10
Effects of short-term experimental insulin resistance and family history of diabetes on pancreatic beta-cell function in nondiabetic individuals.
J Clin Endocrinol Metab. 2005 Oct;90(10):5825-33. doi: 10.1210/jc.2005-0048. Epub 2005 Aug 9.
Zotero 插件